Abatacept Injection, Powder, Lyophilized, For Solution
NDC Package 70409-2187-9

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Abatacept injection is a medication used to treat rheumatoid arthritis, a condition in which the body's own defense system (immune system) attacks healthy tissue. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Bristol-myers Squibb Company, this product is identified by NDC 70409-2187.

Identification & Billing

NDC Package Code
70409-2187-9
Package Description
10.2 kg in 1 BOTTLE
Product Code
70409-2187
11-Digit Billing Format
70409218709

Clinical Specifications

Proprietary Name
Abatacept
Non-Proprietary Name
Abatacept
Substance Name
Abatacept
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Active Ingredient(s)
ABATACEPT 1 kg/kg
Usage Information
This medication is used to treat rheumatoid arthritis, a condition in which the body's own defense system (immune system) attacks healthy tissue. This leads to swelling in the joints, which causes pain and makes it harder to move. Abatacept works by weakening your immune system. This effect helps to slow down joint damage and reduce joint pain and swelling so you can move better. This medication is also used to treat other types of arthritis (such as juvenile idiopathic arthritis, psoriatic arthritis).

Regulatory & Marketing

Labeler Name
Bristol-myers Squibb Company
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
12-19-2011
Listing Expiration
12-31-2027
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70409-2187-9 identifies a specific commercial package of 10.2 kg in 1 bottle of Abatacept (UNFINISHED drug), a bulk ingredient labeled by Bristol-myers Squibb Company. This injection, powder, lyophilized, for solution is formulated for use and contains abatacept as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bristol-myers Squibb Company on December 19, 2011. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat rheumatoid arthritis, a condition in which the body's own defense system (immune system) attacks healthy tissue. This leads to swelling in the joints, which causes pain and makes it harder to move. Abatacept works by weakening your immune system. This effect helps to slow down joint damage and reduce joint pain and swelling so you can move better. This medication is also used to treat other types of arthritis (such as juvenile idiopathic arthritis, psoriatic arthritis).

How is this Bristol-myers Squibb Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70409218709. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70409-2187-9
11-Digit CMS (5-4-2)
70409-2187-09

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.